<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5093">
  <stage>Registered</stage>
  <submitdate>19/09/2013</submitdate>
  <approvaldate>19/09/2013</approvaldate>
  <nctid>NCT01951326</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease</studytitle>
    <scientifictitle>A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease</scientifictitle>
    <utrn />
    <trialacronym>MAPUS</trialacronym>
    <secondaryid>RHB-104-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Crohn's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Crohn's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - RHB-104
Treatment: drugs - Placebo

Active Comparator: RHB-104 - 5 RHB-104 capsules administered orally BID

Placebo Comparator: Placebo - 5 placebo capsules administered orally BID


Treatment: drugs: RHB-104
95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine

Treatment: drugs: Placebo
5 placebo capsules administered orally BID

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Remission at week 26 - Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150</outcome>
      <timepoint>Baseline to week 26</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Response at week 26 - Reduction of CDAI score by a minimum of 100 points</outcome>
      <timepoint>Baseline to week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to remission and response - The time (weeks after randomization) that a subject first records a state of remission or response.</outcome>
      <timepoint>Baseline through week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of remission and response - The time that a subject is in a state of remission or response.</outcome>
      <timepoint>Baseline through week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maintenance of remission - Remission in a subject from week 26 through week 52.</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          1. Signed fully informed consent provided as per this protocol.

          2. Diagnosis of Crohn's Disease confirmed by endoscopy or radiography and/or histology at
             least 6 months prior to randomization into the study.

          3. CD involving the ileum and/or colon

          4. Moderately to severely active CD (Crohn's Disease Activity Index (CDAI) score of
             greater than or equal to 220 and less than or equal to 450) at baseline.

          5. Current treatment with at least one of the following therapies:

             A. Oral 5-acetyl salicylic acid (5-ASA) compounds. Dose must be stable for at least 4
             weeks before baseline.

             B. Corticosteroid therapy. Dose must be stable for at least 2 weeks before baseline.

             C. Azathioprine or 6-mercaptopurine (6-MP) or methotrexate. Dose must be stable for at
             least 8 weeks before baseline.

             D. Infliximab or adalimumab. Dose must be stable for at least 14 weeks before
             baseline.

          6. White blood cell count greater than or equal to 3.5 x 109 at screening.

          7. Active Crohn's disease, defined by at least one of the following: C-reactive protein
             greater than Upper Limit of Normal (ULN) at screening, fecal calprotectin greater than
             Upper Limit of Normal (ULN) at screening, OR radiographic (MRE or CTE) or endoscopic
             confirmation of the presence of active CD within 5 weeks of screening visit. .

          8. Subject agrees to use barrier contraceptive methods (i.e. diaphragm, cervical cap,
             contraceptive sponge or condom) with spermicidal foam/gel/cream/suppository, IUD/IUS
             or progestogen injection (Depo-ProveraÂ®) throughout the study and for at least 6 weeks
             after last study drug administration, unless subject is post-menopausal or otherwise
             incapable of becoming pregnant by reason of surgery or tubal ligation, or has had a
             vasectomy. In regions where local regulatory contraceptive requirements differ, the
             ICF will reflect local policies.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          1. Crohn's Disease involvement isolated to the mouth, upper gastrointestinal tract, or
             anus.

          2. History of total colectomy with ileorectal anastomosis or a proctocolectomy.

          3. Presence of active fistulizing Crohn's Disease or healed fistula within 2 months prior
             to screening.

          4. Subject has postoperative stoma, ostomy, or ileoanal pouch.

          5. Subject has short bowel syndrome.

          6. Subject is scheduled for surgical bowel resection.

          7. Subject has known symptomatic obstructive strictures or bowel perforation in the 6
             months prior to screening.

          8. Change in dose or discontinuation of oral 5-acetyl salicylic acid (5-ASA) compounds
             less than 4 weeks prior to baseline.

          9. Change in dose or discontinuation of corticosteroids less than 2 weeks prior to
             baseline.

         10. Change in dose or discontinuation of azathioprine, 6-mercaptopurine (6-MP) or
             methotrexate less than 8 weeks prior to baseline.

         11. Change in dose or discontinuation of infliximab or adalimumab less than 14 weeks prior
             to baseline.

         12. Treatment with vedolizumab less than 120 days prior to baseline or biological
             therapies (apart from infliximab or adalimumab) less than 60 days prior to baseline.

         13. Previous treatment with rifabutin and/or clofazimine.

         14. Oral or parenteral antibiotics in the 4 weeks prior to baseline (topical antibiotics
             are permitted).

         15. Treatment with probiotics (excluding yogurt and yogurt-derived products) in the 4
             weeks prior to baseline.

         16. Females who have a positive pregnancy test or are lactating.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>330</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Bankstown Hospital, Level 3, Department of Gastroenterology, Eldridge Road - Bankstown</hospital>
    <hospital>Department of Gastroenterology and Hepatology, Concord Hospital, Hospital Road - Concord</hospital>
    <hospital>Nepean Hospital, Derby Street - Kingswood</hospital>
    <hospital>Department of Gastroenterology, Level 1, Clinic 123, New Clinical Building, Liverpool Hospital, Elizabeth St. - Liverpool</hospital>
    <hospital>Department of Gastroenterology and Hepatology, Level 9, Ned Hanlon Building, Royal Brisbane and Women's Hospital Corner Butterfield Street and Bowen Bridge Street - Herston</hospital>
    <hospital>Mater Hospital Brisbane, Department of Gastroenterology, Raymond Terrace - South Brisbane</hospital>
    <hospital>Ballarat Health Services, Drummond St North - Ballarat</hospital>
    <hospital>Department of Gastroenterology, Eastern Health, ECRU, Level 2, 5 Arnold Street - Box Hill</hospital>
    <hospital>Department of Gastroenterology and Hepatology, Cabrini Medical Centre, 183 Wattletree Road - Malvern</hospital>
    <postcode>2200 - Bankstown</postcode>
    <postcode>2139 - Concord</postcode>
    <postcode>2747 - Kingswood</postcode>
    <postcode>2170 - Liverpool</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>3350 - Ballarat</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3144 - Malvern</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sliven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Horovice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Trebovice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Usti nad Labem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Be'er Ya'aqov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Holon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Kfar-Saba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Nahariya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Nazareth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach-Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Olsztyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Sopot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Torun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>LÃ³dz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Kragujevac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Novi Sad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Brezno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Martin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Nitra</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>RedHill Biopharma Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's
      disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01951326</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ira N Kalfus, MD</name>
      <address>RedHill Biopharma</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>